scholarly journals Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: A pilot randomized controlled trial.

2015 ◽  
Vol 83 (3) ◽  
pp. 564-577 ◽  
Author(s):  
Allison G. Harvey ◽  
Adriane M. Soehner ◽  
Kate A. Kaplan ◽  
Kerrie Hein ◽  
Jason Lee ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Randomized Controlled Trial ◽  
Mood State ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Pilot Randomized Controlled Trial

scholarly journals The safety and efficacy of fecal microbiota transplantation in a population with bipolar disorder during depressive episodes: study protocol for a pilot randomized controlled trial

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Noah C. A. Cooke ◽  
Asem Bala ◽  
Johane P. Allard ◽  
Susy Hota ◽  
Susan Poutanen ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Randomized Controlled Trial ◽  
Fecal Microbiota Transplantation ◽  
Therapeutic Option ◽  
Controlled Trial ◽  
Fecal Microbiota ◽  
High Recurrence Rate ◽  
Randomized Controlled ◽  
Depressive Episodes ◽  
Pilot Randomized Controlled Trial

Abstract Background Bipolar disorder (BD) is a chronic, debilitating illness with significant medical morbidity, often secondary to current treatments, and a high recurrence rate. This burden of disease reflects limitations in the tolerability and efficacy of current treatments. There is a compelling body of evidence linking the gut microbiota to mental illness, and while microbial manipulation via probiotic use has been studied as a therapeutic in BD, targeted trials of fecal microbiota transplantation (FMT) have not been conducted in this population. Methods and design We describe a pilot randomized controlled trial of FMT in participants with BD depression to assess the feasibility, efficacy, safety, and tolerability of this intervention. Individuals between 18 and 65 years of age will be enrolled in the study if they meet diagnostic criteria for a major depressive episode of at least moderate severity in the context of a BD diagnosis and have not responded to treatment for BD. Participants will be randomized 1:1 to receive either screened and processed donor stool (allogenic FMT) or their own stool (autologous FMT) via colonoscopy and monitored for 24 weeks post intervention. Depressive and manic symptoms, treatment acceptability, and gastrointestinal and other side effects are assessed at baseline (prior to randomization) and weekly. Stool samples to assess microbiome composition are obtained at baseline and 3 and 6 months. Discussion Currently, FMT represents a novel therapeutic option for treating BD depression. This protocol allows for the assessment of the feasibility, efficacy, acceptability, and safety of an intervention aimed at changing the microbiome in those with BD. Results from this pilot study will guide the development of larger trials of FMT for BD depression and may give more insight into how the gut microbiome are altered in those with BD depression. Trial registration Clinical Trials Gov NCT03279224

Sign in / Sign up

Export Citation Format

Share Document